Eisai’s Leqembi wins accelerated U.S. approval and unlocks broader Medicare coverage for the drug
Leqembi reduced amyloid markers in early Alzheimer's disease and resulted in moderately less decline in measures of cognition and function...
Pharma
TG103 injections may be effective in achieving weight reduction in patients with obesity
1. In this randomized, double-blind, placebo-controlled trial, the use of once-weekly subcutaneous TG103 resulted in significant weight reduction at 12...
Bayer AG: Elinzanetant Shows Promise In Treating Menopause-Associated Vasomotor Symptoms In Phase 3 Clinical Trials
Elinzanetant reduced the frequency and severity of menopause-associated vasomotor symptoms in two phase 3 clinical trials. Elinzanetant was safe and...
Roche: CT-388 Dual GLP1-GIP Receptor Agonist Clinically Improves Weight Loss
Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to...
Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer
In patients with metastatic prostate cancer, ARV-766 treatment led to a greater than 50% reduction in Prostate-Specific antigen (PSA) in...
Reunion Neuroscience: Psychedelic Prodrug RE104 For The Treatment of Post-Partum Depression Moves Into Phase 2 Clinical Trials.
RE104 is a psychedelic prodrug that was safe and well tolerated by healthy participants in a phase 1 clinical trial....
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients
Hemophilia B patients given Beqvez had a decreased incidence of total bleeding Beqvez reduced the use of routine factor IX...
Eli Lilly: Tirzepatide Shows Promise In Treating Obstructive Sleep Apnea In Two Phase 3 Clinical Trials
Tirzepatide led to a 63% mean reduction in restricted/obstructed breathing events per hour in patients with moderate to severe obstructive...
AbbVie: Rinvoq, a monoclonal antibody against JAK enzyme, has superior efficacy in patients with atopic dermatitis compared to Dupixent
20% of patients treated with Rinvoq achieved 90% or greater reduction on the Eczema Area and Severity Index (EASI) and...
Lumicell: Injectable imaging agent illuminates residual breast cancer tissue during surgery to ensure tumor removal.
In the intervention group of 357 patients, 27 had additional removal of residual tumor based on imaging agent-guided technology. Six...